Diabetic Retinopathy Market Size, Share, and Growth Forecast 2026 - 2033

The global diabetic retinopathy market size is expected to be valued at US$ 8.3 billion in 2026 and is projected to reach US$ 12.3 billion by 2033, growing at a CAGR of 5.8% between 2026 and 2033. The rising global diabetes burden is the key factor driving the growth of the market, because every person living with diabetes is at risk of retinal damage. The International Diabetes Federation (IDF) Diabetes Atlas 2025 estimates that 589 million adults aged 20-79 years were living with diabetes in 2024, a number expected to rise to 853 million by 2050.

A meta-analysis published in Ophthalmology estimated that about 103 million people had diabetic retinopathy in 2020, projected to reach roughly 161 million by 2045. Wider screening, longer-acting anti-VEGF therapies, the entry of biosimilars, and growing use of AI-based retinal screening are converting this large patient pool into treated patients.

Drivers - Rising Global Prevalence of Diabetes and Vision-Threatening Retinopathy

The expanding diabetic population is the most significant driver of demand for diabetic retinopathy therapies. According to the IDF, about one in nine adults worldwide is living with diabetes, and more than 40% of them remain undiagnosed, implying a large future treatment pool. In the U.S., the Centers for Disease Control and Prevention (CDC) reports that 38.4 million people have diabetes, while a study published in JAMA Ophthalmology in 2023 estimated that 9.6 million Americans had diabetic retinopathy in 2021, including about 1.84 million with vision-threatening disease.

Diabetic retinopathy remains a leading cause of blindness among working-age adults, according to the World Health Organization (WHO). Longer disease duration, poor glycemic control, hypertension, and rising obesity rates all increase progression risk. As populations age and diabetes onset occurs earlier, demand for retinal monitoring, intravitreal therapy, laser treatment, and surgery is expected to rise steadily through 2033.

Advances in Long-Acting Anti-VEGF Therapies and Biosimilar Uptake

Therapeutic innovation is expanding the treated population and reducing the burden of frequent injections. The U.S. Food and Drug Administration (FDA) approved Roche's Vabysmo (faricimab) for DME in 2022, the first bispecific antibody targeting both VEGF-A and angiopoietin-2, allowing dosing intervals of up to 16 weeks in many patients. Regeneron's EYLEA HD (aflibercept 8 mg) received FDA approval in 2023 for DME and diabetic retinopathy, with dosing every 8 to 16 weeks after initial doses.

In 2025, the FDA approved Genentech's Susvimo port delivery system for DME and diabetic retinopathy, offering refills about every nine months. At the same time, biosimilars such as Samsung Bioepis' Byooviz and Opuviz, Biocon's Yesafili, and Amgen's Pavblu are lowering treatment costs. These developments improve adherence and access, strengthening the wider ophthalmic drugs market.

Restraints - High Treatment Costs and Heavy Injection Burden

The high cost and frequency of intravitreal therapy limit wider adoption, particularly in low- and middle-income countries. Branded anti-VEGF agents can cost more than US$ 1,000 per injection in the U.S., and patients with DME often need 7 to 9 injections in the first year, as shown in trials run by the DRCR Retina Network. Medicare Part B spending on ophthalmic anti-VEGF drugs ranks among the program's highest, which encourages payers to enforce step therapy and prior authorization.

Repeated clinic visits create a significant burden for working-age patients and caregivers. A study published in Ophthalmology found that about 25% of patients with proliferative diabetic retinopathy were lost to follow-up after treatment, which can lead to poorer visual outcomes. These cost and adherence challenges reduce treatment continuity and slow the conversion of diagnosed patients into long-term therapy users.

Low Screening Rates and Shortage of Retinal Specialists

Underdiagnosis and limited access to eye care professionals restrain the market, because untreated patients do not enter the treatment pathway. In the U.S., data from the CDC suggest that only around 60% of adults with diabetes receive an annual dilated eye examination, despite guidance from the American Diabetes Association (ADA) recommending regular screening. Gaps are much wider in developing countries.

The WHO World Report on Vision notes that at least 2.2 billion people globally have a vision impairment, and many low-income regions have fewer than four  ophthalmologists per million people, according to the International Council of Ophthalmology. Rural populations often lack access to retinal imaging and intravitreal injection services. As a result, many patients are diagnosed only at advanced stages, when outcomes are poorer and treatment options are more limited, restricting overall market penetration.

Opportunities - AI-Enabled Screening Expanding Early Diagnosis and Treatment Uptake

Artificial intelligence-based retinal screening represents a significant opportunity to expand the diagnosed and treated patient pool. In 2018, the FDA authorized IDx-DR, now marketed as LumineticsCore by Digital Diagnostics, as the first autonomous AI system to detect more-than-mild diabetic retinopathy without a specialist's interpretation. Eyenuk's EyeArt received FDA clearance in 2020, and AEYE Health's AEYE-DS has since been cleared, including for use with handheld cameras. In Singapore, the Singapore Eye Research Institute (SERI) developed SELENA+, an AI screening system deployed within national programs.

The Centers for Medicare & Medicaid Services (CMS) created a dedicated CPT reimbursement code (92229) for AI-based autonomous retinal imaging, encouraging primary care adoption. By moving screening into primary care clinics and pharmacies, AI tools are expected to identify more patients needing referral, creating downstream demand across the retinal imaging devices market and therapeutic segments.

Emerging Oral, Sustained-Release, and Earlier-Stage Therapies

The development of oral, sustained-release, and earlier-intervention therapies offers strong growth potential, particularly for proliferative and non-proliferative disease. The LENS trial in Scotland, published in NEJM Evidence in 2024, showed that oral fenofibrate reduced progression to referable diabetic retinopathy or maculopathy by about 27% over 4 years, supporting interest in systemic oral therapy. Ocular Therapeutix is developing AXPAXLI, a hydrogel axitinib implant, for NPDR, while Opus Genetics (formerly Ocuphire Pharma) has evaluated oral APX3330 in diabetic retinopathy.

Kodiak Sciences is studying tarcocimab tedromer in diabetic retinopathy with longer dosing intervals, and Clearside Biomedical is advancing suprachoroidal delivery technology. Therapies that treat patients before vision loss occurs can greatly expand the addressable population, as most patients with NPDR are currently managed through observation alone. Successful approvals open a large new revenue pool for innovators.

Disease Type Insights

Non-proliferative diabetic retinopathy (NPDR) is the leading disease type segment, accounting for around 43% share of the market in 2026. NPDR is the most common stage of the disease, and the majority of patients with diabetic retinopathy are diagnosed at this stage through routine screening. The meta-analysis published in Ophthalmology estimated that about 22% of people with diabetes have some form of retinopathy, while only about 6% have vision-threatening disease, indicating that most cases are non-proliferative.

FDA approvals of Regeneron's EYLEA and EYLEA HD for diabetic retinopathy, regardless of DME status, have allowed treatment of moderately severe and severe NPDR, supported by results from the PANORAMA trial. Meanwhile, proliferative diabetic retinopathy (PDR) is projected to be the fastest-growing segment between 2026 and 2033, owing to rising disease duration, better detection, and growing use of anti-VEGF therapy alongside laser and vitrectomy.

Treatment Type Insights

Anti-VEGF drugs are expected to dominate the treatment type category with an estimated 66% share in 2026. These therapies have become the standard of care for center-involved DME and are increasingly used in PDR, supported by evidence from the DRCR Retina Network's Protocol T and Protocol S trials, which showed superior or comparable visual outcomes versus laser photocoagulation. Leading products include EYLEA and EYLEA HD from Regeneron and Bayer, Vabysmo and Lucentis from Roche/Genentech, and Beovu from Novartis, which received FDA approval for DME in 2022.

Off-label bevacizumab is also widely used as a lower-cost option. Biosimilar entry is expanding access in price-sensitive markets. Corticosteroids are projected to register the fastest CAGR through 2033, supported by sustained-release implants for patients who respond suboptimally to anti-VEGF therapy and the need to reduce injection frequency.

Route of Administration Insights

Intravitreal administration is anticipated to hold the largest market share of about 78% in 2026. Most approved disease-modifying therapies for DME and diabetic retinopathy, including anti-VEGF agents and corticosteroid implants such as AbbVie's Ozurdex and ANI Pharmaceuticals' Iluvien, are delivered directly into the vitreous cavity. This route places the drug at the target tissue, achieving high local concentrations while limiting systemic exposure.

The American Academy of Ophthalmology (AAO) notes that intravitreal injections are among the most frequently performed procedures in ophthalmology, with millions of injections administered each year in the U.S. alone. Port delivery systems and long-acting implants are further strengthening this segment. However, the oral segment is expected to grow fastest between 2026 and 2033, supported by positive data for fenofibrate from the LENS trial and pipeline oral candidates targeting earlier-stage disease without invasive procedures.

Distribution Channel Insights

Hospital pharmacies are projected to hold the largest market share of 57% in 2026. Intravitreal injections, laser procedures, and vitrectomy surgeries are mainly performed in hospital ophthalmology departments and hospital-affiliated retina clinics, where biologics are stored under cold-chain conditions and administered by specialists. In many countries, including the U.K., Germany, and France, anti-VEGF drugs are procured through public hospital tenders and dispensed within hospitals.

Hospitals also manage complex patients with PDR who need surgery or combination therapy. In the U.S., many retina practices use a buy-and-bill model, but hospital outpatient departments remain important for high-acuity care. Online pharmacies are expected to record the fastest growth through 2033, driven by rising e-pharmacy adoption, home delivery of oral diabetes and supportive medications, and the potential launch of oral retinopathy therapies.

North America Diabetic Retinopathy Market Trends and Insights

North America is expected to lead the global diabetic retinopathy market with around 38% share in 2026. The region benefits from high diabetes prevalence, strong insurance coverage for intravitreal therapy, and early access to new drugs approved by the FDA and Health Canada. Key trends include rapid adoption of extended-interval therapies such as Vabysmo and EYLEA HD, launch of aflibercept biosimilars, and growth of AI-based autonomous screening in primary care settings.

A dense network of retina specialists and clinical research sites, including the DRCR Retina Network, supports evidence generation and fast uptake of new treatment protocols. Canada contributes further growth through provincial screening programs and expanding public reimbursement of anti-VEGF agents, reinforcing the region's leading position throughout the forecast period. Growing pharmacy-based and retail clinic screening further widens the region's diagnosed patient base.

U.S. Diabetic Retinopathy Market Size

The U.S. diabetic retinopathy market is estimated at about US$ 2.9 billion in 2026, representing nearly 91% of the North American market. Growth is supported by a large patient pool, with about 9.6 million Americans estimated to have diabetic retinopathy, according to research published in JAMA Ophthalmology. High use of branded anti-VEGF drugs, Medicare Part B coverage, and early adoption of new therapies such as Susvimo for diabetic retinopathy strengthen market value. The CMS reimbursement code for AI-based retinal screening is expanding diagnosis in primary care.

The launch of aflibercept biosimilars from 2024 is expected to broaden access while maintaining treatment volumes, supporting steady market expansion through 2033. Rising diabetes rates among Hispanic and Black populations, who face a higher retinopathy burden, further increase long-term treatment needs across the country.

Europe Diabetic Retinopathy Market Trends and Insights

Europe is expected to hold the second-largest share of the market in 2026, supported by universal healthcare coverage, organized screening programs, and growing diabetes prevalence. The IDF estimates that about 66 million adults in the European region live with diabetes. Key trends include rapid uptake of anti-VEGF biosimilars approved by the European Medicines Agency (EMA), cost-containment through national tenders, and growing use of extended-interval agents to reduce clinic capacity pressures.

Several countries are implementing teleophthalmology and AI-assisted screening to handle rising demand. Health technology assessment bodies strongly influence pricing and access, encouraging competition between originator and biosimilar products. Rising patient volumes are expected to offset price erosion and support consistent regional growth through 2033. Expanding diabetic eye screening coverage in Southern and Eastern Europe also creates new treatment demand across the region.

Germany Diabetic Retinopathy Market Size

The Germany diabetic retinopathy market is estimated at about US$ 490 million in 2026, accounting for around 22% of the European market. Germany has one of Europe's largest diabetic populations, with more than 8.5 million people diagnosed, according to the German Diabetes Society (DDG). Statutory health insurance covers intravitreal therapy, and the country has a strong network of ophthalmologists and retina centers.

The Federal Joint Committee (G-BA) evaluates new therapies through the AMNOG benefit assessment process, which shapes pricing. Growing use of biosimilars and long-acting agents, along with an aging population, is expected to sustain steady demand for diabetic retinopathy treatment over the forecast period. Expanding teleophthalmology services in rural states and rising adoption of AI-assisted grading are further improving early detection and referral rates nationwide.

U.K. Diabetic Retinopathy Market Size

The U.K. diabetic retinopathy market is estimated at about US$ 360 million in 2026, representing nearly 16% of the European market. According to Diabetes UK, more than 5.6 million people in the U.K. live with diabetes, including those undiagnosed. The NHS Diabetic Eye Screening Programme in England invites millions of people each year for retinal photography, ensuring early detection and referral.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab for DME, while NHS adoption of anti-VEGF biosimilars is lowering costs and expanding capacity. Ongoing clinic capacity pressures are also driving demand for longer-acting therapies and AI-supported grading. Community-based injection clinics run by trained nurses are also increasing treatment capacity, supporting steady growth in patient volumes through 2033.

France Diabetic Retinopathy Market Size

The France diabetic retinopathy market is estimated at about US$ 335 million in 2026, accounting for roughly 15% of the European market. According to Santé publique France, more than 3.5 million people receive pharmacological treatment for diabetes. National health insurance (Assurance Maladie) covers intravitreal therapy, and the Haute Autorité de Santé (HAS) guides reimbursement decisions for new agents. France has developed retinal screening networks that use non-mydriatic cameras and remote reading by ophthalmologists, improving detection in underserved areas.

Rising diabetes prevalence among older adults and increasing adoption of extended-interval anti-VEGF therapies are expected to support consistent growth through 2033. The country's well-established network of private ophthalmology practices and growing use of biosimilars are also expected to widen patient access to anti-VEGF therapy.

Asia Pacific Diabetic Retinopathy Market Trends and Insights

Asia Pacific is projected to be the fastest-growing market between 2026 and 2033, driven by the world's largest diabetic population and improving access to retinal care. China alone has about 148 million adults living with diabetes, according to the IDF, the highest number globally. China's National Health Commission has promoted chronic disease management and eye health plans that emphasize diabetic retinopathy screening, and domestic companies such as Kanghong Pharmaceutical, with its anti-VEGF drug Conbercept, are expanding treatment options.

Across the region, trends include rising use of AI-based screening, expanding insurance coverage for anti-VEGF drugs, growth of private eye hospital chains, and entry of lower-cost biosimilars, all of which are expected to accelerate treatment uptake. Mature markets in the region add stable demand through established reimbursement systems and high adoption of premium extended-interval therapies.

India Diabetic Retinopathy Market Size

The India diabetic retinopathy market is estimated at about US$ 230 million in 2026, representing nearly 12% of the Asia Pacific market. The ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology in 2023 estimated that 101 million Indians have diabetes and another 136 million have prediabetes. The National Programme for Control of Blindness and Visual Impairment (NPCBVI) includes diabetic retinopathy screening, and eye hospital networks such as Aravind Eye Care System and L V Prasad Eye Institute are using AI-based screening tools.

Domestic biosimilars of ranibizumab are improving affordability, creating strong demand in tier-2 and tier-3 cities through 2033. Expanding coverage under Ayushman Bharat PM-JAY, which provides health insurance to hundreds of millions of citizens, is also improving access to retinal procedures and surgery.

The global diabetic retinopathy market is moderately consolidated, with a small number of companies such as Regeneron Pharmaceuticals, Roche/Genentech, Bayer AG, and Novartis AG accounting for a large share of anti-VEGF revenues. Roche reported Vabysmo sales of about CHF 3.9 billion in 2024 across its approved indications, showing rapid uptake of next-generation agents. Market leaders differentiate through longer dosing intervals, strong clinical evidence, and broad label coverage across DME and diabetic retinopathy.

Biosimilar developers such as Samsung Bioepis, Biocon Biologics, Amgen, and Sandoz are intensifying price competition as aflibercept and ranibizumab patents expire. Mid-sized innovators, including Ocular Therapeutix, Kodiak Sciences, and Clearside Biomedical, focus on sustained-release and novel delivery platforms, while licensing deals, acquisitions, and partnerships with AI screening firms are emerging as key growth strategies.

Key Industry Developments

• May 2025: Genentech, a member of the Roche Group, received FDA approval for Susvimo (ranibizumab injection) to treat diabetic retinopathy, offering continuous drug delivery with refills about every 9 months, following its DME approval earlier in the year.
• June 2024: ANI Pharmaceuticals announced an agreement to acquire Alimera Sciences, the maker of the Iluvien fluocinolone acetonide implant for DME, expanding its retina portfolio; the transaction was completed later in 2024.
• May 2024: Samsung Bioepis and Biogen received FDA approval for Opuviz (aflibercept-yszy), a biosimilar to EYLEA, for indications including DME and diabetic retinopathy, alongside Biocon's Yesafili approval.